Stock to watch – Sequenom (SQNM)

The expected launch of its SEQureDx™ Down syndrome test by Sequenom (SQNM) is delayed, due to the discovery by company officials of employee mishandling of R&D test data and results. Accordingly the company is no longer relying on the previously announced R&D test data and results.

Leave a Reply

Your email address will not be published. Required fields are marked *